Intellia Therapeutics Inc
NTLA9.440USD
-0.150-1.56%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.09BMarket Cap
LossP/E TTM
More Details of Intellia Therapeutics Inc Company
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies. CRISPR is a gene editing technology which is also sometimes referred to as CRISPR/Cas or CRISPR/Cas9 when referring to the use of CRISPR technology with the Cas9 enzyme. Its in vivo product candidates address genetic diseases by deploying its technologies, including CRISPR/Cas9 delivered by LNPs, as the therapy for diseases with high unmet need. Its lead in vivo product candidates, nexiguran ziclumeran (nex-z or NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE), are the first CRISPR-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. For its ex vivo product candidates, it applies its technologies to create engineered cell therapies to address immuno-oncology and autoimmune diseases.
Intellia Therapeutics Inc Info
Ticker SymbolNTLA
Company nameIntellia Therapeutics Inc
IPO dateMay 06, 2016
CEOLeonard (John M)
Number of employees403
Security typeOrdinary Share
Fiscal year-endMay 06
Address40 Erie St Ste 130
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02139-4254
Phone18572856200
Websitehttps://www.intelliatx.com/
Ticker SymbolNTLA
IPO dateMay 06, 2016
CEOLeonard (John M)
Company Executives of Intellia Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. John M. Leonard, M.D.
Dr. John M. Leonard, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
893.46K
+10.09%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
119.97K
+500.83%
Ms. Eliana Clark, Ph.D.
Ms. Eliana Clark, Ph.D.
Executive Vice President, Chief Technology Officer
Executive Vice President, Chief Technology Officer
92.38K
-1.09%
Dr. David Lebwohl, M.D.
Dr. David Lebwohl, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
51.64K
+125.03%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
49.72K
+19.18%
Dr. Georgia Keresty, Ph.D.
Dr. Georgia Keresty, Ph.D.
Independent Director
Independent Director
24.15K
+49.55%
Mr. Brian M. Goff
Mr. Brian M. Goff
Independent Director
Independent Director
23.41K
+51.92%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
18.80K
+74.05%
Dr. Jesse Goodman, M.D.
Dr. Jesse Goodman, M.D.
Independent Director
Independent Director
16.62K
-8.51%
Mr. Michael P. Dube
Mr. Michael P. Dube
Chief Accounting Officer, Vice President
Chief Accounting Officer, Vice President
2.65K
-41.39%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. John M. Leonard, M.D.
Dr. John M. Leonard, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
893.46K
+10.09%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
119.97K
+500.83%
Ms. Eliana Clark, Ph.D.
Ms. Eliana Clark, Ph.D.
Executive Vice President, Chief Technology Officer
Executive Vice President, Chief Technology Officer
92.38K
-1.09%
Dr. David Lebwohl, M.D.
Dr. David Lebwohl, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
51.64K
+125.03%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
49.72K
+19.18%
Dr. Georgia Keresty, Ph.D.
Dr. Georgia Keresty, Ph.D.
Independent Director
Independent Director
24.15K
+49.55%
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
14.24M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Dec 14
Updated: Sun, Dec 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
10.29%
The Vanguard Group, Inc.
9.52%
BlackRock Institutional Trust Company, N.A.
6.56%
Contrarius Investment Management Ltd.
5.08%
State Street Investment Management (US)
4.29%
Other
64.25%
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
10.29%
The Vanguard Group, Inc.
9.52%
BlackRock Institutional Trust Company, N.A.
6.56%
Contrarius Investment Management Ltd.
5.08%
State Street Investment Management (US)
4.29%
Other
64.25%
Shareholder Types
Shareholders
Proportion
Investment Advisor
46.23%
Investment Advisor/Hedge Fund
20.63%
Hedge Fund
12.35%
Research Firm
6.93%
Corporation
3.20%
Individual Investor
1.39%
Bank and Trust
0.54%
Pension Fund
0.25%
Family Office
0.05%
Other
8.44%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
685
93.42M
80.66%
-27.55M
2025Q2
701
102.48M
98.83%
-16.17M
2025Q1
734
106.27M
102.60%
-9.72M
2024Q4
721
99.85M
96.57%
-1.86M
2024Q3
722
94.22M
92.84%
-2.81M
2024Q2
726
90.26M
93.51%
-7.71M
2024Q1
739
91.00M
94.49%
-893.96K
2023Q4
792
85.05M
91.49%
-3.09M
2023Q3
802
83.74M
94.78%
-6.96M
2023Q2
821
81.86M
93.61%
-7.70M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
ARK Investment Management LLC
13.02M
12.13%
+6.86K
+0.05%
Jun 30, 2025
The Vanguard Group, Inc.
10.83M
10.09%
+100.14K
+0.93%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.04M
7.49%
-367.46K
-4.37%
Jun 30, 2025
Contrarius Investment Management Ltd.
1.55M
1.45%
-468.53K
-23.18%
Jun 30, 2025
State Street Investment Management (US)
4.04M
3.76%
-470.98K
-10.44%
Jun 30, 2025
Two Sigma Investments, LP
4.37M
4.07%
+394.37K
+9.92%
Jun 30, 2025
Goldman Sachs & Company, Inc.
1.64M
1.53%
-615.09K
-27.24%
Jun 30, 2025
Regeneron Pharmaceuticals Inc
3.70M
3.45%
--
--
Jun 30, 2025
Morgan Stanley Investment Management Inc. (US)
1.96M
1.82%
+783.72K
+66.91%
Jun 30, 2025
Baker Bros. Advisors LP
2.68M
2.49%
+2.03M
+315.40%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
ARK Genomic Revolution ETF
3.52%
WisdomTree BioRevolution Fund
1.63%
Global X Genomics & Biotechnology ETF
1.38%
ARK Innovation ETF
1.25%
Virtus LifeSci Biotech Clinical Trials ETF
1.02%
Invesco Dorsey Wright Healthcare Momentum ETF
0.95%
State Street SPDR S&P Biotech ETF
0.56%
Tema Heart & Health ETF
0.36%
Direxion Daily S&P Biotech Bull 3X Shares
0.35%
First Trust Small Cap Growth AlphaDEX Fund
0.29%
View more
ARK Genomic Revolution ETF
Proportion3.52%
WisdomTree BioRevolution Fund
Proportion1.63%
Global X Genomics & Biotechnology ETF
Proportion1.38%
ARK Innovation ETF
Proportion1.25%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.02%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion0.95%
State Street SPDR S&P Biotech ETF
Proportion0.56%
Tema Heart & Health ETF
Proportion0.36%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.35%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.29%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Intellia Therapeutics Inc?
The top five shareholders of Intellia Therapeutics Inc are:
ARK Investment Management LLC holds 13.02M shares, accounting for 12.13% of the total shares.
The Vanguard Group, Inc. holds 10.83M shares, accounting for 10.09% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.04M shares, accounting for 7.49% of the total shares.
Contrarius Investment Management Ltd. holds 1.55M shares, accounting for 1.45% of the total shares.
State Street Investment Management (US) holds 4.04M shares, accounting for 3.76% of the total shares.
ARK Investment Management LLC holds 13.02M shares, accounting for 12.13% of the total shares.
The Vanguard Group, Inc. holds 10.83M shares, accounting for 10.09% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.04M shares, accounting for 7.49% of the total shares.
Contrarius Investment Management Ltd. holds 1.55M shares, accounting for 1.45% of the total shares.
State Street Investment Management (US) holds 4.04M shares, accounting for 3.76% of the total shares.
What are the top three shareholder types of Intellia Therapeutics Inc?
The top three shareholder types of Intellia Therapeutics Inc are:
ARK Investment Management LLC
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
ARK Investment Management LLC
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Intellia Therapeutics Inc (NTLA)?
As of 2025Q3, 685 institutions hold shares of Intellia Therapeutics Inc, with a combined market value of approximately 93.42M, accounting for 80.66% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -18.18%.
What is the biggest source of revenue for Intellia Therapeutics Inc?
In FY2025Q2, the -- business generated the highest revenue for Intellia Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
